希少血友病因子の世界市場：市場規模・シェア・動向分析 (因子欠乏症の種類別・薬剤クラス別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

希少血友病因子市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の希少血友病因子の市場規模は2030年までに4億9,040万米ドルに達し、2025年から2030年までのCAGRは6.4％を記録すると予測されています。

米国FDAなどの規制機関から販売承認を取得した複数の濃縮因子が市場成長を大きく後押しすると予想されます。さらに、患者による予防治療の採用が増加していることも、今後数年間の市場成長を後押しすると予想されます。重篤な希少血友病因子障害の患者は、出血エピソードを回避しQOLを向上させるために予防的治療が推奨されています。COVID-19パンデミックは市場成長に大きな影響を与えました。

パンデミックによって患者の安全性と感染対策が重視された結果、特定の凝固因子療法を投与する際の安全対策に対する意識が高まり、重要視されるようになりました。医療提供者と患者は、適切な消毒、手指衛生、個人用保護具の使用など、治療投与中の衛生習慣を守ることをより意識するようになりました。このように患者の安全対策が重視されるようになったことは、希少血友病因子の投与に長期的な利益をもたらす可能性があります。パンデミックがもたらした課題にもかかわらず、希少血友病に対する特異的凝固因子治療に対する需要は依然として高いです。希少型血友病患者は、その病態を効果的に管理し治療するために、依然としてこれらの治療法を必要としていました。

診断率と治療率を高めるための政府の好意的な取り組みや義務付けが市場の成長を後押ししています。例えば、米国議会は1983年に希少疾病用医薬品法（Orphan Drug Act：ODA）を制定しました。1983年から2015年までに約3,647の医薬品がオーファンドラッグに指定され、554の医薬品が米国FDAによって承認されました。市場参入企業は、競争の激しい市場で優位に立つため、革新的な製品の上市や提携などの取り組みを絶えず行っています。例えば、2022年11月、FDAは遺伝性の血液凝固性疾患である血友病Bの治療に対する革新的な遺伝子治療の承認を発表しました。遺伝子ベースの治療薬であるKymriahは、25歳以下のB細胞前駆血友病患者の治療に使用されます。

希少血友病因子市場：分析概要

• 第VII因子欠乏症が市場を独占し、2024年には35.1%のシェアを占める。第XIII因子欠乏症は予測期間中最も速いCAGR 7.1％で成長すると予測されます。
• 遺伝子組換え療法が市場をリードし、2024年には50.3%のシェアを占める。予防的治療は予測期間中に最速のCAGR 7.5%を記録する見込みです。
• 病院薬局は2024年に59.9%の最大シェアを占めました。オンライン薬局は予測期間中に最速のCAGR 9.2％で成長すると予測されます。
• 北米の希少血友病因子市場は、2024年に38.7%の収益シェアを獲得し、世界市場を独占しました。アジア太平洋の希少血友病因子市場は予測期間中に最速のCAGR 6.1％を記録すると予測されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 希少血友病因子市場：変動要因・傾向・範囲

• 市場連関の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• ビジネス環境分析
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 希少血友病因子市場：因子欠乏症の種類別のビジネス分析

• 市場シェア：因子欠乏症の種類別 (2024年・2030年)
• 因子欠乏症の種類別ダッシュボード
• 市場規模の予測と動向分析：因子欠乏症の種類別 (2018～2030年)
• 第VII因子欠乏症
• 第XI因子欠乏症（血友病C）
• 第XIII因子欠乏症
• その他

第5章 希少血友病因子市場：薬剤クラス別のビジネス分析

• 市場シェア：薬剤クラス別 (2024年・2030年)
• 薬剤クラス別ダッシュボード
• 市場規模の予測と動向分析：薬剤クラス別 (2018～2030年)
• 組み換え療法
• 血漿由来療法
• 予防的治療
• その他

第6章 希少血友病因子市場：流通チャネル別のビジネス分析

• 市場シェア：流通チャネル別 (2024年・2030年)
• 流通チャネル別ダッシュボード
• 市場規模の予測と動向分析：流通チャネル別 (2018～2030年)
• 病院薬局
• 小売薬局
• オンライン薬局
• オンライン薬局市場 (2018～2030年)

第7章 希少血友病因子市場：地域別の推定・動向分析

• 市場シェア分析：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 国別 (2018～2030年)
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別 (2018～2030年)
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別 (2018～2030年)
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別 (2018～2030年)
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別 (2018～2030年)
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Novo Nordisk A/S
  • Bayer AG
  • CSL
  • Pfizer Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Swedish Orphan Biovitrum AB（publ）
  • Octapharma AG
  • Grifols, SA
  • BioMarin

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
• Table 4. Global rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 5. Global rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 6. Global rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7. North America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
• Table 8. North America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 9. North America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 10. North America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11. U.S. rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 12. U.S. rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 13. U.S. Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14. Canada rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 15. Canada rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 16. Canada rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Mexico rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 18. Mexico rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 19. Mexico rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20. Europe rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
• Table 21. Europe rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 22. Europe rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 23. Europe rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24. UK rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 25. UK rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 26. UK Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27. Germany rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 28. Germany rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 29. Germany rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. France rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 31. France rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 32. France Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33. Italy rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 34. Italy rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 35. Italy rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36. Spain rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 37. Spain rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 38. Spain rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39. Norway rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 40. Norway rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 41. Norway Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Denmark rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 43. Denmark rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 44. Denmark rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45. Sweden rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 46. Sweden rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 47. Sweden rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48. Asia Pacific rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
• Table 49. Asia Pacific rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 50. Asia Pacific rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 51. Asia Pacific rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52. Japan rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 53. Japan rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 54. Japan rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55. China rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 56. China rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 57. China rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. India rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 59. India rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 60. India rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61. Australia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 62. Australia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 63. Australia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64. South Korea rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 65. South Korea rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 66. South Korea rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Thailand rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 68. Thailand rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 69. Thailand rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70. Latin America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
• Table 71. Latin America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 72. Latin America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 73. Latin America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74. Brazil rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 75. Brazil rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 76. Brazil rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77. Argentina rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 78. Argentina rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 79. Argentina rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa Rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84. South Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 85. South Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 86. South Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90. UAE rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 91. UAE rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 92. UAE rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93. Kuwait rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
• Table 94. Kuwait rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
• Table 95. Kuwait rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Rare hemophilia factors market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Factor deficiency type and drug class outlook (USD Million)
• Fig. 10 Distribution channel outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Rare hemophilia factors market dynamics
• Fig. 13 Rare hemophilia factors market: Porter's five forces analysis
• Fig. 14 Rare hemophilia factors market: PESTLE analysis
• Fig. 15 Rare hemophilia factors market: Factor deficiency type segment dashboard
• Fig. 16 Rare hemophilia factors market: Factor deficiency type market share analysis, 2024 & 2030
• Fig. 17 Factor VII deficiency market, 2018 - 2030 (USD Million)
• Fig. 18 Factor XI deficiency (Hemophilia C) market, 2018 - 2030 (USD Million)
• Fig. 19 Factor XIII deficiency market, 2018 - 2030 (USD Million)
• Fig. 20 Others market, 2018 - 2030 (USD Million)
• Fig. 21 Rare hemophilia factors market: Drug class segment dashboard
• Fig. 22 Rare hemophilia factors market: Drug class market share analysis, 2024 & 2030
• Fig. 23 Recombinant therapies market, 2018 - 2030 (USD Million)
• Fig. 24 Plasma-derived therapies market, 2018 - 2030 (USD Million)
• Fig. 25 Prophylactic treatments market, 2018 - 2030 (USD Million)
• Fig. 26 Others market, 2018 - 2030 (USD Million)
• Fig. 27 Rare hemophilia factors market: Distribution channel segment dashboard
• Fig. 28 Rare hemophilia factors market: Distribution channel market share analysis, 2024 & 2030
• Fig. 29 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 30 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 31 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 32 Rare hemophilia factors market revenue, by region
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 North America rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 36 U.S. country dynamics
• Fig. 37 U.S. rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 38 Canada country dynamics
• Fig. 39 Canada rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 40 Mexico country dynamics
• Fig. 41 Mexico rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 42 Europe rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 43 UK country dynamics
• Fig. 44 UK rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 45 Germany country dynamics
• Fig. 46 Germany rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 47 France country dynamics
• Fig. 48 France rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 49 Italy country dynamics
• Fig. 50 Italy rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 51 Spain country dynamics
• Fig. 52 Spain rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 53 Norway country dynamics
• Fig. 54 Norway rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 55 Sweden country dynamics
• Fig. 56 Sweden rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 57 Denmark country dynamics
• Fig. 58 Denmark rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 59 Asia Pacific rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 60 Japan country dynamics
• Fig. 61 Japan rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 62 China country dynamics
• Fig. 63 China rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 64 India country dynamics
• Fig. 65 India rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 66 Australia country dynamics
• Fig. 67 Australia rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 68 South Korea country dynamics
• Fig. 69 South Korea rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 70 Thailand country dynamics
• Fig. 71 Thailand rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 72 Latin America rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 73 Brazil country dynamics
• Fig. 74 Brazil rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 75 Argentina country dynamics
• Fig. 76 Argentina rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 77 MEA rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 78 South Africa country dynamics
• Fig. 79 South Africa rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 80 Saudi Arabia country dynamics
• Fig. 81 Saudi Arabia rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 82 UAE country dynamics
• Fig. 83 UAE rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 84 Kuwait country dynamics
• Fig. 85 Kuwait rare hemophilia factors market, 2018 - 2030 (USD Million)
• Fig. 86 Company categorization
• Fig. 87 Company market position analysis
• Fig. 88 Strategic framework

Rare Hemophilia Factors Market Growth & Trends:

The global rare hemophilia factors market size is expected to reach USD 490.4 million by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U.S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U.S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

Rare Hemophilia Factors Market Report Highlights:

• Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period.
• Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period.
• Hospital pharmacies held the largest market share of 59.9% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period.
• North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Factor Deficiency Type
  • 1.2.2. Drug Class
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Hemophilia Factors Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Rare Hemophilia Factors Market: Factor Deficiency Type Business Analysis

• 4.1. Factor Deficiency Type Market Share, 2024 & 2030
• 4.2. Factor Deficiency Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Factor Deficiency Type, 2018 to 2030 (USD Million)
• 4.4. Factor VII Deficiency
  • 4.4.1. Factor VII Deficiency Market, 2018 - 2030 (USD Million)
• 4.5. Factor XI Deficiency (Hemophilia C)
  • 4.5.1. Factor XI Deficiency (Hemophilia C) Market, 2018 - 2030 (USD Million)
• 4.6. Factor XIII Deficiency
  • 4.6.1. Factor XIII Deficiency Market, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Rare Hemophilia Factors Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Recombinant Therapies
  • 5.4.1. Recombinant Therapies Market, 2018 - 2030 (USD Million)
• 5.5. Plasma-derived Therapies
  • 5.5.1. Plasma-derived Therapies Market, 2018 - 2030 (USD Million)
• 5.6. Prophylactic Treatments
  • 5.6.1. Prophylactic Treatments Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Rare Hemophilia Factors Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
• 6.7. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Takeda Pharmaceutical Company Limited
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Biogen
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Novo Nordisk A/S
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bayer AG
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. CSL
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Pfizer Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Sanofi
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. F. Hoffmann-La Roche Ltd
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Swedish Orphan Biovitrum AB (publ)
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Octapharma AG
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Grifols, S.A.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. BioMarin
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives